US hypertension-related cardiovascular mortality nearly doubled from 2000 to 2019 while treatment and control rates stagnated for 15 years demonstrating structural access failure not drug unavailability

The JACC inaugural Cardiovascular Statistics report documents that hypertension-related cardiovascular deaths nearly doubled from 23 to 43 per 100,000 population between 2000 and 2019, while treatment and control rates have remained stagnant for 15 years. Nearly 1 in 2 US adults meet current hypertension criteria. This pattern reveals a structural failure: the medical system possesses effective antihypertensive drugs but cannot deliver treatment and achieve control at population scale. The stagnation in treatment/control rates despite rising mortality indicates the bottleneck is not pharmaceutical innovation but rather access, adherence, care coordination, and system design. Disparities persist with higher rates in men and Black adults. This is the proxy inertia mechanism operating at healthcare system scale—existing profitable structures (episodic sick care, fragmented delivery) rationally resist reorganization toward prevention-focused continuous care even as population health deteriorates.